Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome

scientific article

Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1015422699
P356DOI10.1186/S13613-014-0022-Z
P932PMC publication ID4273700
P698PubMed publication ID25593740
P5875ResearchGate publication ID270964902

P50authorMichael MatthayQ93363551
Kevin L DelucchiQ56999240
Angela J RogersQ57319406
Kathleen D LiuQ73785234
Carolyn CalfeeQ90427817
P2093author name stringB Taylor Thompson
Katherine Cosgrove
Xiaohui Fang
David H McKenna
Joseph E Levitt
Hanjing Zhuo
Jeanine P Wiener-Kronish
Kirsten N Kangelaris
Andrew D Leavitt
Jae-Woo Lee
Jeffrey E Gotts
Jennifer G Wilson
Lizette Caballero
Melanie L McMillan
P2860cites workMesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis.Q44486370
Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trialQ44622790
Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndromeQ51708262
Fibroproliferation in late adult respiratory distress syndrome. Pathophysiology, clinical and laboratory manifestations, and response to corticosteroid rescue treatmentQ72300919
The acute respiratory distress syndromeQ84693193
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingQ25938984
Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome NetworkQ27861021
High-frequency oscillatory ventilation for adult respiratory distress syndrome--a pilot studyQ28242127
Acute respiratory distress syndrome: the Berlin DefinitionQ29615138
Incidence and outcomes of acute lung injuryQ29615139
The acute respiratory distress syndromeQ29615140
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care MedicineQ29618869
Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 productionQ29619807
Neuromuscular blockers in early acute respiratory distress syndromeQ34023977
Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1.Q34074353
Efficacy and safety of corticosteroids for persistent acute respiratory distress syndromeQ34515095
Comparison of two fluid-management strategies in acute lung injuryQ34528886
The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adultsQ34991895
Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injuryQ35841729
Treatment of pulmonary arterial hypertensionQ35905944
Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytesQ35994803
Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational managementQ36261456
Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteriaQ36917444
Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lungQ37327475
Predictors of mortality in acute lung injury during the era of lung protective ventilationQ37407868
Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.Q40453111
Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37.Q42013900
Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injuryQ42128038
Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia.Q42176451
Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in miceQ42826405
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P921main subjectacute respiratory distress syndromeQ344873
phase I clinical trialQ5452194
phase II clinical trialQ42824440
P304page(s)22
P577publication date2014-07-03
P1433published inAnnals of Intensive CareQ18712109
P1476titleDesign and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome
P478volume4

Reverse relations

cites work (P2860)
Q42370797Adipose-derived stem cells attenuate pulmonary microvascular hyperpermeability after smoke inhalation
Q96303872Bone marrow-derived humoral factors suppress oxidative phosphorylation, upregulate TSG-6, and improve therapeutic effects on liver injury of mesenchymal stem cells
Q36852274Cellular Therapies in Trauma and Critical Care Medicine: Forging New Frontiers
Q33898175Cellular therapies in trauma and critical care medicine: Looking towards the future
Q51371175Challenges in the cGMP manufacturing of MSCs for multicenter academia trials
Q36459432Chromatographically isolated CD63+CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI
Q38664603Clinical trials in acute respiratory distress syndrome: challenges and opportunities.
Q91595574Ethical development of stem-cell-based interventions
Q28385337LPS impairs oxygen utilization in epithelia by triggering degradation of the mitochondrial enzyme Alcat1
Q96647315MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy
Q34979725Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial
Q87411315Pharmacological agents for adults with acute respiratory distress syndrome
Q38645019Proceedings: Regenerative Medicine for Lung Diseases: A CIRM Workshop Report.
Q57282139Short-term physiological hypoxia potentiates the therapeutic function of mesenchymal stem cells
Q26795447Stem Cells and Regenerative Medicine: Myth or Reality of the 21th Century
Q38442767The Immunomodulatory and Therapeutic Effects of Mesenchymal Stromal Cells for Acute Lung Injury and Sepsis
Q28386068The acute respiratory distress syndrome: from mechanism to translation
Q90746387Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia
Q35604449Therapeutic potential of mesenchymal stromal cells for acute respiratory distress syndrome
Q36253821Therapeutic targeting of acute lung injury and acute respiratory distress syndrome
Q93219844Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Search more.